You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Authors' response
  1. Shomron Ben-Horin1,
  2. Yehuda Chowers2
  1. 1Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Israel
  2. 2Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel
  1. Correspondence to Shomron Ben-Horin, Gastroenterology Department, Sheba Medical Center, Tel Hashomer 52621, Israel; sben-horin{at}013.net.il

https://doi.org/10.1136/gut.2011.239699

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Vande Casteele and colleagues for their interest in our work and commend them for their interesting case.1 2 As written in our manuscript, we have had several, and in some cases serial, measurements of infliximab and antidrug antibody (ADA) levels in the patients reported. However, we limited the results to the last sample available before loss of response occurred to better meet the aim of the study, which was to investigate the immunogenic fragment of infliximab and its possible diagnostic role in …

    View Full Text

    Footnotes

    • Linked article 236869.

    • Competing interests Shomron Ben-Horin and Yehuda Chowers have served as consultants to Abbot and Schering-Plough.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles